Skip to main content

Table 2 Autoantibodies and drug-induced lupus under infliximab

From: The role of tumor necrosis factor-alpha in systemic lupus erythematosus

   New ANA New anti-dsDNA New ACLA   
Diagnosis Number Positive Positivea IgM IgG IgM IgG DIL Reference
RA 156 37 (24%) 22 (14%) 22 1 ND ND 1 [20]
RA 62 19 (31%) 7 (11%) 7 0 ND ND 0 [22]
RA 24 4 (17%) 13 (54%) 9–11 3–4 5 0 0 [24]
RA 59 24 (41%) 21 (36%) 19 2 ND ND 0 [26]
RA 53 29 (55%) 5 (9%) 22b 34b 0 0 2 [27]
RA 59 24 (41%) 29 (49%) 28 1 0 0 0 [28]
RA 57 28 (49%)   ND 3 ND ND 1 [31]
All RA 413 165 (40%) 77 (19%)      4 (1.0%)  
AS 15 9 (60%) 4 (27%) 4 0–1 1 3 0 [24]
SpA 21 12 (57%) 4 (19%) ND ND ND ND 0 [21]
SpA 35 25 (71%) 6 (17%) 6 0 ND ND 0 [22]
SpA 33 8 (24%) 11 (33%) 11 0 ND ND 0 [29]
All SpA 94 54 (57%) 25 (27%)      0 (0%)  
CD 35 6 (17%) 3 (9%) ND ND ND ND 0 [23]
CD 125 71 (57%) 14 (11%) ND ND ND ND 2 [25]
CD 500 ND ND ND ND ND ND 3 [35]
CD 63 21 (33%) 9 (14%) ND 9 2 0 1 [30]
All CD 723        6 (0.8%)  
All together 1,230        10 (0.8%)  
  1. aRadioimmunoassay or most conservative value reported; bvalues difficult to reconcile with the number of patients with anti-dsDNA antibodies as measured by radioimmunoassay. ACLA, anti-cardiolipin antibodies; ANA, anti-nuclear antibodies; anti-dsDNA, antibodies to double-stranded DNA; AS, ankylosing spondylitis; CD, Crohn disease; DIL, drug-induced lupus; Ig, immunoglobulin; ND, not determined/reported; RA, rheumatoid arthritis; SpA, spondylarthropathies.